N@N

Market Maker Surveillance Report. BVSN, REGN, FLML, HGSI, OCLS, LOGL, Winning Stocks With Lowest Price Friction For Wednesday,

September 21, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 3785 companies with "abnormal" market making, 1317 companies with positive Friction Factors and 5202 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. BROADVISION INC (NASDAQ:BVSN), REGENERON PHARMACEUTICALS INCORPORATED (NASDAQ:REGN), FLAMEL TECHNOLOGIES-SP ADR (NASDAQ:FLML), HUMAN GENOME SCIENCES INC (NASDAQ:HGSI), OCULUS INNOVATIVE SCIENCES I (NASDAQ:OCLS), LEGEND OIL AND GAS LTD (OTC:LOGL). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     BVSN       $0.820       9.79%        46,397          63.70%       26,438          36.30%       19,959          243     
     REGN       $5.930       9.22%        2,371,874       48.14%       2,349,568       47.69%       22,306          38      
     FLML       $0.680       15.21%       94,947          54.75%       78,259          45.13%       16,688          245     
     HGSI       $1.630       12.54%       6,387,103       53.38%       5,581,305       46.65%       805,798         4,944   
     OCLS       $0.330       27.05%       323,464         62.06%       197,035         37.80%       126,429         3,831   
     LOGL       $0.280       13.66%       135,189         51.40%       69,724          26.51%       65,465          2,338   

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows BVSN with a dollar gain Wednesday of $0.82000 and a Friction Factor of 243 shares. That means that it only took 243 more shares of buying than selling to move BVSN higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

BROADVISION INC (NASDAQ:BVSN) - BroadVision, Inc. develops, markets, and supports enterprise portal applications. Its applications enable companies to unify their e-business infrastructure and conduct both interactions and transactions with employees, partners, and customers through a personalized self-service model. The companys solutions include business agility suite, which enables interaction with visitors through personalized views of information, resources, and business processes stored in diverse internal and external legacy information systems. It also offers commerce agility suite that allows businesses to manage business-to-business and business-to-consumer channels through a single solution; OnDemand solution that provides visibility and agility for various members of organizations to collaborate; Clearvale, an integrated Enterprise 2.0 platform; and QuickSilver, which provides features for creation and publishing of documents supporting multiple output formats. In addition, BroadVision offers application services, including commerce services to display product offerings and transact business on Web sites; portal services to provide end users with a personalized and intuitive navigation as they interact with business; process services that extend Web capabilities, and transforms processes and collaborations into Web-based self-service applications; and content services to manage Web content. Further, the company provides staging services to simplify the process of moving content from multiple systems to the production environment; eMerchandising to create, manage, and implement sales discounts while maintaining oversight over profitability; and search solution that provides text and field searching of online content. BroadVision serves financial services, government, healthcare, manufacturing, retail, and telecommunications industries in the Americas, Europe, the Asia Pacific, and the Middle East. The company was founded in 1993 and is headquartered in Redwood City, California.

REGENERON PHARMACEUTICALS INCORPORATED (NASDAQ:REGN) - Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The companys commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical trials include Rilonacept for the prevention and treatment of gout-related flares; VEGF Trap-Eye for eye diseases using intraocular delivery; and Aflibercept for the treatment of oncology. The companys earlier stage clinical programs REGN475, an antibody to nerve growth factor, which is being developed for the treatment of pain; REGN88, an antibody to the interleukin-6 receptor, which is developed in rheumatoid arthritis; REGN421, an antibody to delta-like ligand-4, for the treatment of oncology; REGN727, an antibody to proprotein convertase substilisin/kexin type 9, which is developed for low density lipoprotein cholesterol reduction; and REGN668, an antibody to the interleukin-4 receptor for certain allergic and immune conditions. Regeneron Pharmaceuticals also conducts other preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company has strategic collaboration with sanofi-aventis Group to discover, develop, and commercialize fully human monoclonal antibodies; and Bayer HealthCare LLC for the development of the VEGF-Trap-Eye. Regeneron Pharmaceuticals was founded in 1988 and is based in Tarrytown, New York.

FLAMEL TECHNOLOGIES-SP ADR (NASDAQ:FLML) - Flamel Technologies S.A., a biopharmaceutical company, engages in the development of polymer-based drug delivery technologies for life science applications in France. The company develops products based on its nanoparticle Medusa technology, which provides controlled release following injection of therapeutic proteins, peptides, and other large and small molecules; multiparticle Micropump technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement; and Trigger-Lock technology to minimize the misuse and abuse of medications subject to abuse. Its products under development based upon Medusa technology include Interferon-alpha, a naturally occurring protein that the body uses for the treatment of Hepatitis C virus; and FT-105 long-acting basal insulin formulation to meet the basal insulin requirements of diabetic patients. The companys products based on its Micropump technology comprise Trigger Lock, an application that provides a technical solution for the societal problems of intentional and unintentional abuse and misuse of narcotics and other dangerous drugs; and Coreg CR, a formulation of carvedilol phosphate, which is used for the treatment of moderate to severe congestive heart failure, left ventricular dysfunction following myocardial infarction, and hypertension. Flamel Technologies has strategic alliance with Baxter International, Inc.; GlaxoSmithKline; Merck Serono; Pfizer; Corning S.A; and Corning Incorporated. The company was founded in 1990 and is headquartered in Venissieux, France.

HUMAN GENOME SCIENCES INC (NASDAQ:HGSI) - Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. The companys mid- and early-stage pipeline products comprise Mapatumumab for the treatment of non-small cell lung cancer, multiple myeloma, and hepatocellular cancer; IAP Inhibitors that are compounds, which block the activity of IAP (inhibitor of apoptosis) proteins, allowing apoptosis to proceed and causing the cancer cells to die; and CCR5 mAb, a human monoclonal antibody to the CCR5 receptor for the treatment of ulcerative colitis. Human Genome Sciences, Inc. also holds financial rights to certain products in the GlaxoSmithKline clinical development pipeline, including darapladib, a Phase III clinical trial product for the treatment of coronary heart disease and ischemic stroke; and Albiglutide for the treatment for type 2 diabetes, which is in Phase III clinical trial stage. The company has a license agreement with GlaxoSmithKline for the co-development and commercialization of BENLYSTA; and a collaboration and license agreement with Aegera Therapeutics, Inc. to develop and commercialize certain oncology molecules and related backup compounds. Human Genome Sciences, Inc. was founded in 1992 and is headquartered in Rockville, Maryland.

OCULUS INNOVATIVE SCIENCES I (NASDAQ:OCLS) - Oculus Innovative Sciences, Inc. develops, manufactures, and markets tissue care products based on Microcyn platform technology to treat infections and enhance healing while reducing the need for antibiotics. Its Microcyn platform technology, a solution of electrically charged oxychlorine small molecules, treats various organisms that cause disease or pathogens, including viruses, fungi, spores, and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in wounds, as well as Clostridium difficile. The company offers Microcyn-based products primarily through its Website, and various regional distributors principally in the United States, Europe, and Mexico. It sells its products to hospitals, physicians, and nurses; and other healthcare practitioners, who are the caregivers to patients being treated for acute or chronic wounds, as well as those patients undergoing surgical procedures. The company was formerly known as Micromed Laboratories, Inc. and changed its name to Oculus Innovative Sciences, Inc. in August 2001. Oculus Innovative Sciences was incorporated in 1999 and is based in Petaluma, California.

LEGEND OIL AND GAS LTD (OTC:LOGL) -

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net